Friday, September 11

Browsing: randomized

Research

Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial

By NewsCancerAugust 28, 20260

Currently, osimertinib is the standard of care in patients with resected stage II–IIIA EGFR-mutated NSCLC globally. Meanwhile, both osimertinib and…

Research

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

By NewsCancerAugust 13, 20260

Patient disposition and baseline characteristicsBetween September 2019 and June 2022, a total of 717 Chinese patients were enrolled and screened…

Research

Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer

By NewsCancerAugust 10, 20260

Baseline characteristics and treatmentBetween August 18, 2022, and March 5, 2024, 63 patients were enrolled and randomized: 25 were assigned…

Research

Low-fat dietary pattern and dietary advanced glycation end-products intake: a secondary analysis of the Women’s Health Initiative randomized trial

By NewsCancerJuly 28, 20260

In the current analysis, a low-fat dietary pattern was associated with reductions in dAGE intake over 7 years of follow-up.…

Research

OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)

By NewsCancerJuly 18, 20260

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer J Clin. 2024;74:12–49. Google Scholar Descamps G, Karaca…

Research

Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial

By NewsCancerJuly 6, 20260

PatientsFrom February 20, 2021, to July 8, 2024, 358 patients were screened for eligibility (detailed reasons for screening failure are…

Diagnosis

50 Randomized Clinical Trial of Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy (COPE Study)

By NewsCancerJune 24, 20260

BackgroundRadiation therapy (RT) is a critical component of treatment for women with stage 0–IIIA breast cancer, yet initiating RT can…

Research

Association between concomitant ACEI/ARBs use and survival of patients with prostate cancer receiving abiraterone acetate: A post-hoc analysis of two randomized trials

By NewsCancerJune 13, 20260

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates…

Research

Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial

By NewsCancerMay 22, 20260

The phase III FAMILY trial demonstrated a clinically meaningful and statistically significant improvement in PFS with fulvestrant maintenance therapy compared…

Diagnosis

104 KATSIS-1: Randomized Phase 3 Trial Evaluating KAT6 Inhibitor PF-07248144 (prifetrastat) Plus Fulvestrant in HR+HER2− Advanced/Metastatic Breast Cancer After Progression on CDK4/6 Inhibitor-Based Therapy

By NewsCancerMay 20, 20260

BackgroundPatients with hormone receptor–positive (HR+)/HER2-negative (HER2–) advanced/metastatic breast cancer who have tumors that progressed after CDK4/6 inhibitor (CDK4/6i) and endocrine…

What's Hot

αTIGIT-guided IL-15 mimetics drive potent and safe antitumor immunity by restoring tumor-infiltrating T cells

Ofirnoflast Shows Activity Across High-Risk Mutated MDS Subtypes

EPCORE FL-1 Shows Efficacy and Safety of Epcoritamab Combination Therapy

Browsing: randomized

Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer

Low-fat dietary pattern and dietary advanced glycation end-products intake: a secondary analysis of the Women’s Health Initiative randomized trial

OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117)

Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial

50 Randomized Clinical Trial of Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy (COPE Study)

Association between concomitant ACEI/ARBs use and survival of patients with prostate cancer receiving abiraterone acetate: A post-hoc analysis of two randomized trials

Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial

104 KATSIS-1: Randomized Phase 3 Trial Evaluating KAT6 Inhibitor PF-07248144 (prifetrastat) Plus Fulvestrant in HR+HER2− Advanced/Metastatic Breast Cancer After Progression on CDK4/6 Inhibitor-Based Therapy

αTIGIT-guided IL-15 mimetics drive potent and safe antitumor immunity by restoring tumor-infiltrating T cells

Ofirnoflast Shows Activity Across High-Risk Mutated MDS Subtypes

EPCORE FL-1 Shows Efficacy and Safety of Epcoritamab Combination Therapy

What Faster Pharmacokinetics Mean for Detecting Small Brain Metastases

αTIGIT-guided IL-15 mimetics drive potent and safe antitumor immunity by restoring tumor-infiltrating T cells

Ofirnoflast Shows Activity Across High-Risk Mutated MDS Subtypes

EPCORE FL-1 Shows Efficacy and Safety of Epcoritamab Combination Therapy

What Faster Pharmacokinetics Mean for Detecting Small Brain Metastases

Latest Post

αTIGIT-guided IL-15 mimetics drive potent and safe antitumor immunity by restoring tumor-infiltrating T cells

Ofirnoflast Shows Activity Across High-Risk Mutated MDS Subtypes

EPCORE FL-1 Shows Efficacy and Safety of Epcoritamab Combination Therapy

Subscribe to Updates

What's Hot

Browsing: randomized